Search Results

1 - 5 of 5 items :

  • "disease-modifying treatments" x
Clear All
Strategies to Enhance the Intravenous Treatment Satisfaction and Drug Safety Awareness Among Patients with Multiple Sclerosis in Macedonia

Abstract

Background: Multiple sclerosis (MS) treatment aims not only to prevent the rate of relapse, but also to slow down patient’s disability progression. Monoclonal antibodies constitute a new class of therapeutic agents and are administered by intravenous (IV) infusion. Treatment satisfaction and incidence of adverse drug events influence the patient’s treatment adherence which is essential to ensure patients obtain the best treatment outcomes and also to make that treatment cost-effective. Our primary objective was to assess the current IV treatment satisfaction among MS patients.

Methods: A standard questionnaire was developed which contained 20 questions about patient’s disease, IV treatment satisfaction and drug safety awareness. Analyzed data was presented as a percent of the respondents.

Results: The cross-sectional study included 13 MS patients on IV treatment, with mean age of 35 years. 54% of them had relapse-remitting MS, while 46% had secondary progressive MS. The most common onset symptoms were tingling reported in 46% and numbness in 31% patients. 70% of patients were satisfied, while 23% were not satisfied with the conditions under which they were receiving their IV treatment that lasts in average 2 hours. Well-established pharmacovigilance practice enhanced the patient’s knowledge that was reflected through 100% reporting of adverse drug reactions in the past.

Conclusion: High level of satisfaction from the current IV treatment conditions and high drug safety awareness among MS patients was shown. Establishment of infusion centre as a proposed strategy by MS patients would substantially increase their IV treatment satisfaction and adherence.

Open access
in PRILOZI
Clinical and laboratory study of pro-inflammatory and anti-inflammatory cytokines in women with multiple sclerosis

References 1. Hartung H-P, Bar-Or A, Zonkas I. What do we know about the mechanism of action of disease-modifying treatment in MS. J Neurol 2004;251 (Suppl 5): 12-19. 2. Weber F. Effects of autoreactive T cells and cytokines in the pathogenesis of multiple sclerosis. Int MSJ 2001;9(1):29-35. 3. Lubetzki C, Zale B. Myelin repair in multiple sclerosis. In: Antel S, Birnbaum G, Hartung H-P, Vincent A, eds. Clinical Neuroimmunology. New York: Oxford University Press; 2005:399-402. 4. Wilkins

Open access
A potential therapeutic role in multiple sclerosis for stigmast-5,22-dien-3β-ol myristate isolated from Capparis ovata

of Capparis ovata water extract used as an alternative and complementary treatment for multiple sclerosis. Journal of Neuroimmunology 2014; 275: 172-173. 14. Ozgun- Acar O, Celik-Turgut G, Gazioglu I, Kolak U, Ozbal S, Ergur BU, Arslan S, Sen A, Topcu G. Capparis ovata treatment suppresses inflammatory cytokine expression and ameliorates experimental autoimmune encephalomyelitis model of multiple sclerosis in C57BL6 mice. Journal of Neuroimmunology 2016; 298: 106-116. 15. Torkildsen O, Myhr KM, Bo L. Disease-modifying treatments for

Open access
Antiaging phenotype in skeletal muscle after endurance exercise is associated with the oxidative phosphorylation pathway

.pone.0000465 Melov S Tarnpolsky MA Beckman K Felkey K Hubbard A Resistance exercise reverses aging in human skeletal muscle PLoS One 2007 2 e465 12 Ahlskog JE, Geda YE, Graff-Radford NR, Petersen RC. Physical exercise as a preventive or disease-modifying treatment of dementia and brain aging. Mayo Clin Proc. 2011; 86:876-84. 10.4065/mcp.2011.0252 Ahlskog JE Geda YE Graff-Radford NR Petersen RC Physical exercise as a preventive or disease-modifying treatment of dementia and brain aging Mayo Clin Proc 2011 86 876 84 13 Guadalupe-Grau A, Fuentes T, Guerra B, Calbet JAL

Open access
Multiple sclerosis lesions on magnetic resonance imaging, their characterization and pathological correlation with musculoskeletal disability in Pakistanis

2 lesions correspond with the MS plaques, these lesions lack pathological specificity being driven by inflammation, demyelination, edema, and axonal loss and remyelination [ 15 ]. White matter T2W lesion load has frequently been included in treatment trials to assess the response to the disease modifying treatment and assess disease progression [ 16 ]. While the presence of demyelinating lesions in the cortex has been long known, their significance has been largely ignored [ 17 ]. This is because, at least in part, in conventional MRI most of lesions in the gray

Open access